Welcome to our dedicated page for Retractable Tech news (Ticker: RVP), a resource for investors and traders seeking the latest updates and insights on Retractable Tech stock.
Retractable Technologies, Inc. (NYSE American: RVP) is a manufacturer of safety medical products, and the news surrounding RVP reflects both its operating performance and developments in its product portfolio. Company press releases highlight its VanishPoint® syringes, blood collection, and IV catheter products, EasyPoint® retractable needles, and Patient Safe® syringes, all of which are designed with safety features aimed at reducing needlestick injuries, preventing product reuse, and lowering the risk of bloodstream infections from catheter hub contamination.
News updates for Retractable commonly include quarterly and annual financial results, where the company reports net sales, operating income or loss, and the effects of tariffs, product mix, and domestic versus international sales on its margins. These releases often discuss the impact of tariffs on needles, syringes, and other products imported from China, and describe the company’s efforts to increase U.S.-based manufacturing and adjust its workforce and sourcing strategy.
RVP news also covers corporate actions such as dividends on its Series II Class B and Series III Class B Convertible Preferred Stock, which are announced by the Board of Directors and documented in accompanying Form 8-K filings. Operational updates, including workforce reductions in manufacturing and general and administrative functions, are disclosed through press releases and tied to the company’s shift toward greater domestic production.
Product-related announcements, such as the EasyPoint® Blood Collection Tube Holder with Needle receiving an Innovative Technology designation from Vizient®, appear in the company’s news flow as well. These items describe how specific products are evaluated by healthcare experts for their potential impact on patient and worker safety and healthcare operations.
Investors and observers who follow RVP news can review this stream of earnings releases, tariff and manufacturing commentary, preferred stock dividend declarations, and product recognition announcements to understand how Retractable’s safety-focused medical device business is evolving over time.
Retractable Technologies, Inc. (NYSE American: RVP) reported a significant increase in operating income, reaching $36.1 million for the first six months of 2021, up from $1.4 million in the prior year. Income applicable to common shareholders was $28.5 million, compared to $3.7 million the previous year. Net sales for the quarter ended June 30, 2021, were $42.5 million, with the U.S. government accounting for 64.4% of sales. Domestic revenues surged 325.0%, driven by increased government orders.
Retractable Technologies, Inc. (RVP) has approved a stock repurchase plan for up to $10 million, starting June 18, 2021. This plan will run until June 18, 2022, and is designed to enhance shareholder value in response to the stock's perceived undervaluation. The company will also distribute $5,056,945 in dividends to its Class B Convertible Preferred shareholders, including amounts in arrears, with payments scheduled for July 22, 2021. CEO Thomas J. Shaw acknowledged shareholder patience and highlighted the company's commitment to providing essential safety products.
Retractable Technologies, Inc. (RVP) announced an amendment to delivery order 75A50120F33003 from the Department of Health and Human Services, extending the performance end date from May 2021 to March 2022. The amendment reallocates orders to increase shipments of 1mL low dead-space safety syringes. The total contract price and freight costs remain unchanged. The company emphasizes potential challenges, including COVID-19 impacts, liquidity issues, and foreign trade risks among others, that could affect future performance.
Retractable Technologies, Inc. (NYSE American: RVP) has received preliminary notice from the U.S. Department of Health and Human Services to exercise all seven one-month option periods under contract 75A50121P00021, extending the contract's expiration to February 14, 2022. This extension increases the contract's value by $92,772,680, covering products and freight reimbursement costs.
Retractable Technologies Inc. (NYSE American: RVP) has amended its Technology Investment Agreement with the U.S. government, securing an additional $27.4 million in funding. This increase aims to boost domestic manufacturing capabilities by at least 50% to meet ongoing COVID-19 countermeasure demands. The funding will be used to expand production of 1mL low dead-space safety syringes by adding new assembly lines and expanding facilities in Little Elm, Texas. The modification effort is scheduled to be completed by January 31, 2022.
Retractable Technologies, Inc. (NYSE American: RVP) reported a significant increase in operating income to $23.4 million for Q1 2021, a sharp rise from $481 thousand a year prior. U.S. government sales accounted for 75.5% of total revenues, highlighting a 484.7% increase in domestic sales. Additionally, the company had its $1.36 million PPP loan forgiven. However, operating expenses increased 50%, driven by higher headcount and related costs. Overall, domestic unit sales surged 282.6%, although international revenues decreased by $1.5 million.
Retractable Technologies, Inc. (RVP) received preliminary notice from the U.S. Department of Health and Human Services (HHS/ASPR) regarding its intent to exercise two one-month options under a contract dated February 2021. This move extends the contract's expiration from July 14, 2021, to September 14, 2021, correlating to an overall purchase price of approximately $23.5 million, inclusive of freight costs. The contract contains seven total option periods.
Retractable Technologies, Inc. (NYSE American: RVP) has declared dividends of $39,050 for holders of its Series II Class B Convertible Preferred Stock, amounting to $0.25 per share. These dividends, which accrued at 10% per annum, cover arrears from December 31, 2020, through the applicable conversion date of March 31, 2021. Payment is scheduled for April 22, 2021, to shareholders of record by April 12, 2021. Retractable manufactures safety medical products aimed at preventing needlestick injuries and infections, distributing items like the VanishPoint® syringe and Patient Safe® syringes.
Retractable Technologies, Inc. (RVP) reported significant growth in 2020, with operational income rising to approximately $24 million from $3 million in 2019. Revenues surged by 74%, driven primarily by demand for syringes due to COVID-19 vaccinations, with the U.S. government accounting for 39% of total revenues. Domestic sales increased by 131%, while international sales saw a decline of 19%. Operating expenses rose by 16%. New contracts with the U.S. government totaled approximately $138 million, supporting future production expansions. Cash flow from operations improved significantly to $19 million.
Retractable Technologies, Inc. (NYSE American: RVP) declared dividends for its Series I Class B and Series II Class B Convertible Preferred Stock. The dividends total $10,041 for Series I and $39,050 for Series II, equating to $0.125 and $0.25 per share, respectively. The accrual period spans from October 1, 2020, to the date of conversion or December 31, 2020. Payments are scheduled for January 29, 2021, with a record date of January 19, 2021, for Series II stockholders. The company specializes in safety medical products aimed at reducing needlestick injuries and infection risks.